The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy

详细信息    查看全文

• 作者：Ming Jia^* ; ^&dagger ; ; ² ; ^{14111230007@fudan.edu.cn} ; Yuan Xu^* ; ^&dagger ; ; ² ; ^{14111230023@fudan.edu.cn} ; Meiling Zhu^&Dagger ; ; ^{anniezhu_79@163.com} ; Mengyun Wang^* ; ^&dagger ; ; ^{wangmengyun1120@163.com} ; Menghong Sun^&dagger ; ; ^§ ; ; ^{menghongs@163.com} ; Ji Qian^¶ ; ; ^{qianji2012@126.com} ; Jianhua Chang^&dagger ; ; ^# ; ^{changjianhua@163.com} ; Qingyi Wei^* ; ^&dagger ; ; ^** ; ^{weiqingyi@yahoo.com} ; ^{qingyi.wei@duke.edu}
• 刊名：Translational Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：9
• 期：6
• 页码：531-539
• 全文大小：743 K
• 卷排序：9

文摘

The JNK and P38α pathways play an important role in the sensitivity and outcomes of chemotherapy. We hypothesize that functional single nucleotide polymorphisms (SNPs) of genes of these pathways modulate outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy (PBC). We selectively genotyped 11 independent, potentially functional SNPs of 9 genes in the JNK and P38α pathways first in a discovery group of 355 patients with advanced NSCLC treated with PBC, and we evaluated their associations with progression-free survival (PFS) and overall survival (OS) by Cox proportional hazards regression analysis. Then, resultant significant SNPs were further validated in a replication group of 355 patients. In both discovery and validation groups as well as their combined analysis, the MAPK14 rs3804451GA/AA genotypes showed a strong association with a reduced PFS (adjusted hazards ratio [HR] = 1.39; 95% confidence interval [CI] = 1.16–1.66; P = .0003) and OS (adjusted HR = 1.41; 95% CI = 1.11-1.80; P = .005) compared with the wild-type GG genotype. In contrast, patients with or without the MAPK14 rs3804451A allele had no significant difference in OS in response to tyrosine-kinase inhibitor treatment (adjusted HR = 0.86; 95% CI = 0.56-1.33; P = .505). The present study provides evidence that the MAPK14 rs3804451 G>A variant may modulate survival outcomes in patients with advanced NSCLC treated with PBC. Larger studies of additional patient populations are needed to validate our findings.